Edition:
United Kingdom

Verona Pharma PLC (VRNA.OQ)

VRNA.OQ on NASDAQ Stock Exchange Global Market

10.50USD
8:59pm GMT
Change (% chg)

$-0.50 (-4.55%)
Prev Close
$11.00
Open
$10.50
Day's High
$10.87
Day's Low
$10.50
Volume
2,178
Avg. Vol
979
52-wk High
$25.01
52-wk Low
$10.19

Latest Key Developments (Source: Significant Developments)

Verona Pharma Presents Data from Clinical Trials Evaluating RPL554 in Cystic Fibrosis
Friday, 26 Oct 2018 

Oct 26 (Reuters) - Verona Pharma PLC ::DATA FROM CLINICAL AND PRE-CLINICAL TRIALS EVALUATING VERONA PHARMA’S RPL554 IN CYSTIC FIBROSIS PRESENTED AT NORTH AMERICAN CYSTIC FIBROSIS CONFERENCE.PHASE 2A RESULTS DEMONSTRATE RPL554 HAS FAVORABLE PHARMACOKINETIC AND PHARMACODYNAMIC PROFILE IN CYSTIC FIBROSIS PATIENTS.RPL554 DEMONSTRATED A STATISTICALLY SIGNIFICANT INCREASE IN AVERAGE FEV IN PATIENTS TREATED WITH 1.5 MG.  Full Article

Verona Pharma Files For Mixed Shelf Of Upto $200 Mln
Tuesday, 22 May 2018 

May 22 (Reuters) - Verona Pharma PLC ::VERONA PHARMA PLC FILES FOR MIXED SHELF OF UPTO $200 MILLION - SEC FILING.  Full Article

Verona Pharma Says Positive Top-Line Data From Phase 2B Trial Of RPl554
Monday, 26 Mar 2018 

March 26 (Reuters) - Verona Pharma Plc ::VERONA PHARMA REPORTS POSITIVE TOP-LINE DATA FROM PHASE 2B CLINICAL TRIAL OF RPL554 FOR MAINTENANCE TREATMENT OF COPD.PRIMARY ENDPOINT MET; RPL554 PRODUCED CLINICALLY AND STATISTICALLY SIGNIFICANT IMPROVEMENTS IN LUNG FUNCTION AT ALL DOSES.VERONA PHARMA - CLINICALLY RELEVANT SECONDARY ENDPOINTS WERE ALSO MET, INCLUDING STATISTICALLY SIGNIFICANT, PROGRESSIVE IMPROVEMENTS IN COPD SYMPTOMS.RPL554 WAS WELL TOLERATED AT ALL DOSE LEVELS IN THIS FOUR WEEK 400 PATIENT STUDY.  Full Article